Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
156 hedge funds and large institutions have $663M invested in Terns Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 23 closing their positions.
130% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 23
96% more call options, than puts
Call options by funds: $8.73M | Put options by funds: $4.45M
48% more capital invested
Capital invested by funds: $447M → $663M (+$216M)
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
24% more funds holding
Funds holding: 126 → 156 (+30)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.24% less ownership
Funds ownership: 101.4% → 94.16% (-7.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.6M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$13.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.9M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$9.29M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.83M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$7.65M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
US Bancorp
Minneapolis,
Minnesota
| – | -$4.09K | -600 | Closed |
|
177
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$679 | -100 | Closed |
|
|
AF
178
Allworth Financial
Folsom,
California
| – | -$764 | -90 | Closed |
|
179
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$181 | +22 | +1,100% |
|
TERN Hedge Fund Activity: Q3 2024 in Review
156 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q3 2024, worth a combined $663M — up 48% from $447M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new TERN positions and 23 closed out — a net gain of 30 holders — while 53 added to existing stakes and 37 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $18.2M. The largest seller was Fidelity Investments, cutting an estimated $13.1M.
- 156 institutional investors held Terns Pharmaceuticals (TERN) as of Q3 2024, up from 126 in Q2 2024.
- Funds reported $663M of Terns Pharmaceuticals stock for Q3 2024, up 48% quarter-over-quarter.
- 53 funds opened new Terns Pharmaceuticals positions in Q3 2024 and 23 closed out, a net change of +30 holders.
- The largest Terns Pharmaceuticals buyer in Q3 2024 was Citadel Advisors, an estimated $18.2M added.
- The largest Terns Pharmaceuticals seller in Q3 2024 was Fidelity Investments, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2024.